Mark Youssef

Mark Youssef

Auto-generated profile, based on publicly available information

Mark Youssef

Department of Medicine, University of Toronto, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2022 in JMIR Data
Verified
Journal Article
Open access
LMLawrence Mbuagbaw
Lawrence Mbuagbaw
DJDiya Jhuti
Diya Jhuti
GZGohar Zakaryan
Gohar Zakaryan
HEHussein El-Kechen
Hussein El-Kechen
NRNadia Rehman
Nadia Rehman
OMOluwatoni Makanjuola
Oluwatoni Makanjuola
Background: The Joint United Nations Programme on HIV/AIDS has set targets for 2025 regarding people living with HIV. For these targets to be met, 95% of people with HIV would need to know their HIV status, 95% of people with HIV would need to be receiving antiretroviral therapy, and 95% of people on antiretroviral therapy would need to be virally suppressed. Some countries are on track to meet these targets. However, within and across countries, several vulnerable populations may not meet these targets. This is in part because several approaches to improving the cascade of care after an HIV diagnosis are not tailored to and are not appropriate for vulnerable populations, such as men who have sex with men, sex workers, people who inject drugs, Black people, people in prisons, women, and youth. To inform research, policy, and practice, there is a need for curated data on HIV care cascade research. Objective: The CASCADE database is a repository of randomized clinical HIV trials. It was designed to inform, support, and improve HIV care cascade research, systematic reviews, and evidence maps. Methods: PubMed, Embase, CINAHL, PsycINFO, Web of Science, and the Cochrane Library were searched to obtain randomized trials that were designed to address at least one of the following care cascade outcomes: the initiation of therapy, adherence to medication, retention in care, and engagement in care. Data were screened and extracted in duplicate using DistillerSR software (Evidence Partners Incorporated) and were cataloged based on the following features: year, income level, setting, the delivery of the intervention, the population receiving the intervention, intervention type, and the level of pragmatism of the intervention. Results: A total of 298 HIV clinical trials are included in the CASCADE database, of which 162 (54.4%) were conducted in high-income countries, and 116 (38.9%) targeted vulnerable populations. Adherence to antiretroviral therapy was the most investigated HIV care cascade outcome (216/298, 72.5%), followed by retention in care (34/298, 11.4%). CASCADE has a user-friendly interface with simple and advanced search features. The CASCADE database has inspired 2 methodological papers and 13,567 website visits from over 10 countries. Conclusions: CASCADE is the first database dedicated to trials that focus on the HIV care cascade, and it can be used for systematic reviews, evidence maps, and methodological research. It is freely accessible, and the data can be downloaded in CSV format.

11 April 2024 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
MYMark Youssef
Mark Youssef
MSMarina Boutros Salama
Marina Boutros Salama
NRNadia Rehman
Nadia Rehman
CHChristina Hanna
Christina Hanna
MWMary Rose Waniss
Mary Rose Waniss
LMLawrence Mbuagbaw
Lawrence Mbuagbaw
Introduction People living with HIV (PLHIV) have a higher risk of developing pulmonary hypertension (PH) with subsequent poorer prognosis. This review aimed to determine the (1) survival outcomes and (2) proportion of emergency department (ED) visits and hospitalisations of PLHIV and PH. Methods We conducted a systematic review and meta-analysis of observational studies reporting survival outcomes for PLHIV and PH. Electronic databases (Medline, EMBASE, PubMed, Web of Science, Global Index Medicus and Cochrane Library), trial registries and conference proceedings were searched until 22 July 2023. We pooled similar measures of effect, assessed apriori subgroups and used meta-regression to determine mortality and associated variables. Results 5248 studies were identified; 28 studies were included with a total of 5459 PLHIV and PH. The mean survival (95% CI) of PLHIV and PH was 37.4 months (29.9 to 44.8). Participants alive at 1, 2 and 3 years were 85.8% (74.1% to 95.0%), 75.2% (61.9% to 86.7%) and 61.9% (51.8% to 71.6%), respectively. ED visits and hospitalisation rates were 73.3% (32.5% to 99.9%) and 71.2% (42.4% to 94.2%), respectively. More severe disease, measured by echocardiogram, was associated with poorer prognosis (β −0.01, 95% CI −0.02 to 0.00, p=0.009). Survival was higher in high-income countries compared with lower-income countries (β 0.50, 95% CI 0.28 to 0.73, p<0.001) and in Europe compared with the America (β 0.56, 95% CI 0.37 to 0.75, p<0.001). Conclusion Our study confirms poor prognosis and high healthcare utilisation for PLHIV and PH. Prognosis is associated with country income level, geographic region and PH severity. This highlights the importance of screening in this population. PROSPERO registration number CRD42023395023.

1 December 2018 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
LMLawrence Mbuagbaw
Lawrence Mbuagbaw
GMGian Paolo Morgano
Gian Paolo Morgano
DLDaeria O. Lawson
Daeria O. Lawson
ANAgatha Nyambi
Agatha Nyambi
MYMark Youssef
Mark Youssef
LTLehana Thabane
Lehana Thabane

25 October 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
MYMark Youssef
Mark Youssef
BZBabalwa Zani
Babalwa Zani
OOOluwatobi Olaiya
Oluwatobi Olaiya
MSMichael Soliman
Michael Soliman
LMLawrence Mbuagbaw
Lawrence Mbuagbaw
Background To evaluate the definition of HIV virological outcomes in the literature and factors associated with outcomes and missing outcome data. Methods We conducted a methodological review of HIV RCTs using a search (2009–2019) of PubMed, Embase and the Cochrane Central Register of Controlled Trials. Only full-text, peer-reviewed, randomised controlled trials (RCTs) that measured virological outcomes in people living with HIV, and published in English were included. We extracted study details and outcomes. We used logistic regression to identify factors associated with a viral threshold ≤50 copies/mL and linear regression to identify factors associated with missing outcome data. Results Our search yielded 5847 articles; 180 were included. A virological outcome was the primary outcome in 73.5% of studies. 89 studies (49.4%) used virological success. The remaining used change in viral load (VL) (33 studies, 18.3%); virological failure (59 studies, 32.8%); or virological rebound (9 studies, 5.0%). 96 studies (53.3%) set the threshold at ≤50 copies/mL; and 33.1% used multiple measures. Compared with government and privately funded studies, RCTs with industry funding (adjusted OR 6.39; 95% CI 2.15 to 19.00; p<0.01) were significantly associated with higher odds of using a VL threshold of ≤50 copies/mL. Publication year, intervention type, income level and number of patients were not associated with a threshold of ≤50 copies/mL. Trials with pharmacological interventions had less missing data (β=−11.04; 95% CI −20.02 to −1.87; p=0.02). Discussion Country source of funding was associated with VL threshold choice and studies with pharmacological interventions had less missing data, which may in part explain heterogeneous virological outcomes across studies. Multiple measures of VL were not associated with missing data. The development of formal guidelines on virological outcome reporting in RCTs is needed.